Electronic Supplementary Information

Switchable 19F MRI Polymer Theranostics: Towards In Situ Quantifiable Drug Release

A. V. Fuchs, A. P. Bapat, G. J. Cowin and K. J. Thurecht

a Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, 4072, Australia.
b Centre for Advanced Imaging, University of Queensland, Brisbane, 4072, Australia.
c ARC Centre of Excellence in Convergent Bio-Nano Science and Technology.
E-mail: k.thurecht@uq.edu.au

Figure S1. $^1$H NMR (500 MHz, DMSO-$d_6$) of DTX-ketone.
Figure S2. (a) $^1$H (400 MHz) and (b) $^{13}$C (101 MHz) NMR of 2-((2-hydroxyethyl)disulfanyl)ethyl methacrylate in CDCl$_3$.

Figure S3. (a)$^1$H (400 MHz) and (b) $^{13}$C (101 MHz) NMR of CPT-SS-MA in CDCl$_3$. 
**Figure S4.** $^{19}\text{F}$ NMR (471 MHz, DMSO-d$_6$) spectra of HBP-CPT (top), HBP-DTX, HBP-DOX, HBP-deprotected and, HBP-protected (bottom).

**Figure S5.** $^{19}\text{F}$ $T_2$ decay curves at various time points of HBP-DTX in PBS pH 7 and 5 (471 MHz, 10% D$_2$O).